Evidence map›Paper›PMID 39467899›Full record

ArticleInternational journal of hematology2024

Clinical characteristics in adolescents and young adults with polycythemia vera and essential thrombocythemia in Japan.

Yuka Sugimoto, Keiki Nagaharu, Eiko Ohya, Kohshi Ohishi, Isao Tawara, Tomoki Ito, Akihiko Gotoh, Mika Nakamae, Fumihiko Kimura, Michiaki Koike and 18 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Yuka SugimotoDepartment of Hematology and Oncology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan. yuka2@clin.medic.mie-u.ac.jp.ORCID http://orcid.org/0000-0002-3263-3270
Keiki NagaharuDepartment of Hematology and Oncology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.
Eiko OhyaDepartment of Hematology and Oncology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.
Kohshi OhishiDepartment of Hematology and Oncology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.
Isao TawaraDepartment of Hematology and Oncology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.
Tomoki ItoFirst Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
Akihiko GotohDepartment of Hematology, Tokyo Medical University, Shinjuku, Japan.
Mika NakamaeDepartment of Hematology, Osaka Metropolitan University Graduate School of Medicine, Suita, Japan.
Fumihiko KimuraDivision of Hematology, National Defense Medical College, Tokorozawa, Japan.
Michiaki KoikeDepartment of Hematology, Juntendo University Shizuoka Hospital, Izunokuni, Japan.
Keita KiritoDepartment of Hematology & Oncology, University of Yamanashi, Yamanashi, Japan.
Hideho WadaDepartment of Hematology, Kawasaki Medical School, Kurashiki, Japan.
Kensuke UsukiDepartment of Hematology, NTT Medical Center Tokyo, Shinagawa, Japan.
Takayuki TanakaDepartment of Hematology, Tottori Prefectural Central Hospital, Tottori, Japan.
Takehiko MoriDivision of Hematology, Keio University School of Medicine, Shinjuku, Japan.
Satoshi WakitaDepartment of Hematology, Nippon Medical School, Bunkyo, Japan.
Toshiki I SaitoClinical Research Center, NHO Nagoya Medical Center, Nagoya, Japan.
Akiko M SaitoClinical Research Center, NHO Nagoya Medical Center, Nagoya, Japan.
Kazuya ShimodaDivision of Hematology, Diabetes and Endocrinology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Toshiro KurokawaDepartment of Hematology, Toyama Red Cross Hospital, Toyama, Japan.
Akihiro TomitaDepartment of Hematology, Fujita Health University School of Medicine, Toyoake, Japan.
Yoko EdahiroDepartment of Hematology, Juntendo University School of Medicine, Bunkyo, Japan.
Yoshinori HashimotoDepartment of Hematology, Tottori Prefectural Central Hospital, Tottori, Japan.
Hitoshi KiyoiDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Koichi AkashiDepartment of Medicine and Biosystemic Science, Kyushu University, Fukuoka, Japan.
Itaru MatsumuraDepartment of Hematology and Rheumatology, Kindai University Faculty of Medicine, Higashiosaka, Japan.
Katsuto TakenakaClinical Immunology and Infectious Diseases, Ehime University, Matsuyama, Japan.
Norio KomatsuJuntendo University School of Medicine, Bunkyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report the first large-scale retrospective cohort study on adolescent and young adult (AYA) polycythemia vera (PV) and essential thrombocythemia (ET) in Japan, a subgroup analysis using Japanese multicenter registry data (JSH-MPN-R18). This study included patients with PV (n = 31) or ET (n = 141) aged 20 to 39 years at the initial visit. Hemorrhage-free survival (HFS) was better in AYA ET than in non-AYA ET (5-year HFS: 100% vs. 88.6%, p < 0.01), which might be attributed to differences in antithrombotic treatment rates between AYA and non-AYA patients. Although thrombosis-free survival did not differ statistically, the percentage of venous thrombotic events (TEs) among total TEs was higher in AYA compared to non-AYA PV and ET in Japan (26.0% vs. 6.0%, p < 0.01), but much lower than figures reported in European or US cohorts. Cytoreductive therapy (CRT) was administered to 25.8% of AYA patients with PV and 43.3% of AYA patients with ET, and the reason was usually unrelated to high risk of thrombosis. These results could be used to develop a more appropriate strategy for managing PV and ET in the Japanese AYA population.

Indexed as

Polycythemia VeraThrombocythemia, EssentialAdolescentAdultFemaleHemorrhageHumansJapanMaleRegistriesRetrospective StudiesThrombosisYoung AdultAdolescent and young adult (AYA)Bleeding eventsEssential thrombocythemia (ET)Polycythemia vera (PV)Thrombotic events

Identifiers

PMID39467899

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.